Eli Lilly, Walmart Team Up to Offer Affordable Zepbound

Eli Lilly and Company and Walmart Inc. have announced a new collaboration aimed at improving access to affordable obesity treatments.

Through this partnership, Zepbound (tirzepatide) single-dose vials will soon be available for pickup at Walmart pharmacies nationwide by mid-November.

These vials can be purchased through LillyDirect, Lilly’s direct-to-consumer platform, which offers self-pay pricing—providing patients with discounts of 50% or more compared to the list prices of other incretin (GLP-1) medicines for obesity.

All approved strengths of Zepbound vials will be offered, with the starting dose priced at $349 per month under the self-pay option. Patients with a valid, on-label prescription can purchase Zepbound directly, without needing to go through insurance. The partnership with Walmart aims to make obtaining Zepbound more convenient, particularly for individuals who prefer picking up their medication at a nearby Walmart pharmacy.

Also Read: Shilpa Medicare Opens Flow Chemistry Centre in Bengaluru

Zepbound is a prescription injectable medication designed to help adults with obesity or overweight adults with weight-related health issues lose excess weight and maintain their results. It is also indicated for the treatment of adults with moderate to severe obstructive sleep apnea (OSA) who have obesity, to help improve their OSA symptoms.

The medication should be used alongside a reduced-calorie diet and increased physical activity.

Zepbound contains tirzepatide and should not be used in combination with other tirzepatide-containing products or any GLP-1 receptor agonist medications. The safety and effectiveness of Zepbound in children have not yet been established.